Ovid Therapeutics Inc. Insider Trading Activity

PAPADOPOULOS STELIOS reported acquisition or exercise transactions in this Form 4 filing.

Accepted by SEC EDGAR 04/09/2026 - 05:15 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

PAPADOPOULOS STELIOS reported acquisition or exercise transactions in this Form 4 filing.

Ovid Therapeutics director Stelios Papadopoulos received a stock-based compensation award in the form of restricted stock units. The grant covers 17,578 shares of common stock valued at $2.56 per share, replacing a $45,000 annual cash retainer. The RSUs vest 25% at grant and 25% on each of June 30, 2026, September 30, 2026 and December 31, 2026, contingent on continued board service. After this award, he holds 217,578 common shares directly.

Insider Trade Summary

Grant/Award: 17,578 shares

Grant/Award 1 txn

Insider PAPADOPOULOS STELIOS

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	17,578	$2.56	$45K

Holdings After Transaction: Common Stock — 217,578 shares (Direct)

Holdings Before and After: Common Stock, 200,000 to 217,578 shares (Direct)

Footnotes (1)

1. F1. Represents a restricted stock unit ("RSU") award issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of an annual cash retainer for service on the Issuer's Board of Directors in the aggregate amount of $45,000. The RSUs vest 25% upon grant and 25% on each of June 30, 2026, September 30, 2026 and December 31, 2026, subject to the Reporting Person's continuous service through each such vesting date.

Key Figures

RSU award size: 17,578 shares Grant value per share: $2.56 per share Cash retainer replaced: $45,000 +1 more

4 metrics

RSU award size 17,578 shares Restricted stock unit grant to director Stelios Papadopoulos

Grant value per share $2.56 per share Price per share used for the RSU award

Cash retainer replaced $45,000 Annual cash board retainer replaced by RSU award

Shares held after grant 217,578 shares Total common stock directly held after RSU award

Key Terms

restricted stock unit ("RSU"), Non-Employee Director Compensation Policy, annual cash retainer, vesting

4 terms

restricted stock unit ("RSU") financial

"Represents a restricted stock unit ("RSU") award issued to the Reporting Person"

Non-Employee Director Compensation Policy financial

"pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of an annual cash retainer"

annual cash retainer financial

"in lieu of an annual cash retainer for service on the Issuer's Board of Directors in the aggregate amount of $45,000"

vesting financial

"The RSUs vest 25% upon grant and 25% on each of June 30, 2026, September 30, 2026 and December 31, 2026"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PAPADOPOULOS STELIOS

(Last) (First) (Middle)

C/O OVID THERAPEUTICS INC.

441 NINTH AVENUE, 14TH FLOOR

(Street)

NEW YORK NEW YORK 10001

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Ovid Therapeutics Inc. [ OVID ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/07/2026		A(1)		17,578	A	$2.56	217,578	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a restricted stock unit ("RSU") award issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of an annual cash retainer for service on the Issuer's Board of Directors in the aggregate amount of $45,000. The RSUs vest 25% upon grant and 25% on each of June 30, 2026, September 30, 2026 and December 31, 2026, subject to the Reporting Person's continuous service through each such vesting date.

	/s/ Jeffrey Rona, Attorney-in-Fact	04/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)